147 related articles for article (PubMed ID: 11098484)
61. The oral fluorinated pyrimidines.
de Bono JS; Twelves CJ
Invest New Drugs; 2001; 19(1):41-59. PubMed ID: 11291832
[TBL] [Abstract][Full Text] [Related]
62. Oral fluoropyrimidines: are they the equivalent of parenteral infusional 5-fluorouracil?
Lokich J
Cancer Invest; 2001; 19(8):854-7. PubMed ID: 11768039
[No Abstract] [Full Text] [Related]
63. Genetic polymorphisms of enzymes related to oral tegafur/uracil therapeutic efficacy in patients with hepatocellular carcinoma.
Fushiya N; Takagi I; Nishino H; Akizuki S; Ohnishi A
Anticancer Drugs; 2013 Jul; 24(6):617-22. PubMed ID: 23571497
[TBL] [Abstract][Full Text] [Related]
64. Fluorouracil and the new oral fluorinated pyrimidines.
Kuhn JG
Ann Pharmacother; 2001 Feb; 35(2):217-27. PubMed ID: 11215843
[TBL] [Abstract][Full Text] [Related]
65. Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes.
Saif MW; Choma A; Salamone SJ; Chu E
J Natl Cancer Inst; 2009 Nov; 101(22):1543-52. PubMed ID: 19841331
[TBL] [Abstract][Full Text] [Related]
66. Pharmacokinetic modulation of plasma 5-fluorouracil concentrations to potentiate the antitumor activity of continuous venous infusion of 5-fluorouracil.
Fujii S; Fukushima M; Shimamoto Y; Shirasaka T
Jpn J Cancer Res; 1989 Jun; 80(6):509-12. PubMed ID: 2503471
[TBL] [Abstract][Full Text] [Related]
67. A combined pharmacokinetic-pharmacodynamic (PK-PD) model for tumor growth in the rat with UFT administration.
Sung JH; Dhiman A; Shuler ML
J Pharm Sci; 2009 May; 98(5):1885-904. PubMed ID: 18803264
[TBL] [Abstract][Full Text] [Related]
68. Effects of UFT (mixed compound of tegafur and uracil) on cell kinetics and inhibition of thymidylate synthase in L1210 ascites tumor.
Kagawa Y; Ohkubo T; Higashigawa M; Ido M; Kakito H; Inagaki S; Kojima M; Ooi K; Sakurai M
Cancer Invest; 1995; 13(5):470-4. PubMed ID: 7552812
[TBL] [Abstract][Full Text] [Related]
69. 1-(2-Tetrahydrofuryl)-5-fluorouracil in combination with uracil suppresses mammary carcinogenesis and growth of tumors induced with 7,12-dimethylbenz[a]anthracene in rats.
Sakamoto S; Kudo H; Suzuki S; Sassa S; Yoshimura S; Nakayama T; Maemura M; Mitamura T
Anticancer Drugs; 1996 Feb; 7(2):199-203. PubMed ID: 8740726
[TBL] [Abstract][Full Text] [Related]
70. The history, mechanism and clinical use of oral 5-fluorouracil derivative chemotherapeutic agents.
Tanaka F; Fukuse T; Wada H; Fukushima M
Curr Pharm Biotechnol; 2000 Sep; 1(2):137-64. PubMed ID: 11467334
[TBL] [Abstract][Full Text] [Related]
71. Pharmacokinetics of 5-fluorouracil in elderly Japanese patients with cancer treated with S-1 (a combination of tegafur and dihydropyrimidine dehydrogenase inhibitor 5-chloro-2,4-dihydroxypyridine).
Fujita K; Nakayama H; Ichikawa W; Yamamoto W; Endo H; Nagashima F; Tanaka R; Miya T; Sunakawa Y; Yamashita K; Mizuno K; Ishida H; Araki K; Narabayashi M; Miwa K; Ando Y; Akiyama Y; Kawara K; Hirose T; Sasaki Y
Drug Metab Dispos; 2009 Jul; 37(7):1375-7. PubMed ID: 19389859
[TBL] [Abstract][Full Text] [Related]
72. The Role of Fluoropirimidines in Gastrointestinal Tumours: from the Bench to the Bed.
Hernando-Cubero J; Matos-García I; Alonso-Orduña V; Capdevila J
J Gastrointest Cancer; 2017 Jun; 48(2):135-147. PubMed ID: 28397102
[TBL] [Abstract][Full Text] [Related]
73. [Evolving 5-Fluorouracil Therapy to Achieve Enhanced Efficacy-Past and Current Efforts of Researchers].
Maehara Y; Oki E; Saeki H; Tokunaga E; Kitao H; Iimori M; Niimi S; Kataoka Y; Emi Y; Kakeji Y; Baba H; Shirasaka T
Gan To Kagaku Ryoho; 2016 Jul; 43(7):845-54. PubMed ID: 27431628
[TBL] [Abstract][Full Text] [Related]
74. Clinical implications of 5-FU modulation.
Rustum YM
Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):22-5. PubMed ID: 10442354
[TBL] [Abstract][Full Text] [Related]
75. Feasibility of measuring 5-fluorouracil catabolic potential by oral loading.
Watabe S; Sengoku H; Kawai K; Matsuda M; Sakamoto K; Kamano T
J Int Med Res; 2005; 33(5):501-6. PubMed ID: 16222882
[TBL] [Abstract][Full Text] [Related]
76. Fluorouracil (5FU) pharmacokinetics in 5FU prodrug formulations with a dihydropyrimidine dehydrogenase inhibitor.
Peters GJ; van Groeningen CJ; Giaccone G
J Clin Oncol; 2001 Nov; 19(22):4267-9. PubMed ID: 11709571
[No Abstract] [Full Text] [Related]
77. New anticancer agents in clinical development.
Eckardt J; Eckhardt G; Villalona-Calero M; Drengler R; Von Hoff D
Oncology (Williston Park); 1995 Dec; 9(12):1321-8; 1331; discussion 1332-4. PubMed ID: 8771106
[TBL] [Abstract][Full Text] [Related]
78. Thymidylate synthase inhibition as a predictor of tumor sensitivity of fluorinated pyrimidines.
Suzuki M; Sekiguchi I; Tamada T
Asia Oceania J Obstet Gynaecol; 1990 Jun; 16(2):175-80. PubMed ID: 2116122
[TBL] [Abstract][Full Text] [Related]
79. The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites.
Pratt S; Shepard RL; Kandasamy RA; Johnston PA; Perry W; Dantzig AH
Mol Cancer Ther; 2005 May; 4(5):855-63. PubMed ID: 15897250
[TBL] [Abstract][Full Text] [Related]
80. Oral fluoropyrimidines in the treatment of colorectal cancer.
Bissett D; Ahmed F; McLeod H; Cassidy J
Clin Oncol (R Coll Radiol); 2000; 12(4):240-5. PubMed ID: 11005692
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
